---
figid: PMC9360236__ajcr0012-2966-f11
pmcid: PMC9360236
image_filename: ajcr0012-2966-f11.jpg
figure_link: /pmc/articles/PMC9360236/figure/fig11/
number: Figure 11
figure_title: ''
caption: 'The prognostic roles of ITGB1-DT-related genes in NSCLC patients. A. AC025031.5;
  B. AL162578.1; C. APCDD1L; D. AREG; E. ARL14; F. CCK; G. CDK5R2; H. CIDEC; I. CR391992.1;
  J. CREB3L3; K. CRHR2; L. DKK1; M. EREG; N. FEZF1; O. FIBCD1; P. FLNC; Q. FSIP2;
  R. GPR78; S. HSD17B13; T. INSYN2B. Note: NSCLC, non-small cell lung cancer.'
article_title: Interfering with ITGB1-DT expression delays cancer progression and
  promotes cell sensitivity of NSCLC to cisplatin by inhibiting the MAPK/ERK pathway.
citation: Dan Li, et al. Am J Cancer Res. 2022;12(7):2966-2988.
year: '2022'

doi: ''
journal_title: American Journal of Cancer Research
journal_nlm_ta: Am J Cancer Res
publisher_name: e-Century Publishing Corporation

keywords:
- ITGB1-DT
- MAPK
- NSCLC
- overall survival
- disease-specific survival
- progression-free interval

---
